On March 21,
2024, the signing ceremony for the pilot project between the Innovation
Alliance (SMIA) and the "AI Diagnosis and Treatment Committee for Rare
Diseases" (hereafter referred to as the AI Committee) took place at the
Peninsula Beijing Hotel. Geng Yili, the rotating president of SMIA, and Paul Li,
the chairman of the AI Committee, signed a memorandum of cooperation on the
"Pilot Project for AI Diagnosis and Prevention of Rare Diseases."
Both parties conducted in-depth discussions on the content of the cooperation
and future developments, reaching a consensus.
Mr.Paul Li
has extensive experience in the multinational pharmaceutical industry, having
held positions at Eli Lilly, Abbott, Merck, Cephalon, Zhuojian Medical, Jack
Berlin, and other multinational companies. He possesses unique insights into
the diagnosis, treatment, and prevention of rare diseases and has the ability
to integrate global resources to promote industry innovation. Under his
leadership, the AI Committee will utilize advanced scientific and technological
innovations such as big data, cloud computing, the Internet of Things, artificial
intelligence, and mobile internet, as well as shared innovation models. This
will drive public welfare innovation in AI diagnosis, treatment, medication,
and payment for rare diseases, providing compliant and operational solutions
for all parties in the medical and pharmaceutical ecosystems of the Greater Bay
Area, Yangtze River Delta, and Beijing-Tianjin-Hebei regions. The AI Committee
will also formulate corresponding service norms and quality standards.
The pilot
project of the AI Committee aims to form a value-closed loop within the
"government-hospital-doctor-insurance/patient-commercial-manufacturer-pharmacy-third-party
service units" ecosystem, achieving service sharing, business symbiosis,
and innovation for the benefit of all ecosystem participants. This will offer
rare disease patients in China a new experience of "AI Diagnosis and
Prevention + Public Welfare Sharing Model," enhance hospital
informatization, intelligence, precision, and convenience, increase resource
sharing, reduce the need for patients to visit hospitals frequently, and
improve public satisfaction and a sense of achievement.
The core
mission of the AI Committee's pilot project is to be patient-centered, using AI
for diagnosis and prevention as a link, and based on information technology,
intelligence, and standardized public welfare services, to create an
"all-ecosystem sharing platform for rare disease diagnosis and
treatment," achieving collaboration among medical institutions,
pharmaceuticals, and social sectors.
